Approval · Notice of Compliance 222 · 2003
SENSORCAINE: Notice of Compliance 222
Issued July 15, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 222
- Date
- July 15, 2003
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revised product monograph: separate product monograph for sencorcaine forte from that of the other sensorcaine products
- Therapeutic class
- Local anesthetic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SENSORCAINE | Not yet assigned | — |
| SENSORCAINE WITH EPINEPHRINE | Not yet assigned | — |
| SENSORCAINE SPINAL | Not yet assigned | — |
| SENSORCAINE FORTE | Not yet assigned | — |
Medicinal ingredients
- BUPIVACAINE HYDROCHLORIDE 2.5 MG per ML
- BUPIVACAINE HYDROCHLORIDE 5 MG per ML
- BUPIVACAINE HYDROCHLORIDE 7.5 MG per ML
- EPINEPHRINE BITARTRATE 5 MCG per ML